A Phase III, Single-Center, Open-labeled, Randomized Controlled Study Assessing Injection Pain of Preservative-free Makena (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women
Phase of Trial: Phase III
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Hydroxyprogesterone (Primary) ; Hydroxyprogesterone (Primary)
- Indications Preterm labour
- Focus Therapeutic Use
- Sponsors AMAG Pharmaceuticals
- 26 Jun 2017 Status changed from active, no longer recruiting to completed.
- 11 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Oct 2016 New trial record